- Home
- YXT vs RNXT Comparison
YXT vs RNXT Comparison
Compare YXT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- RNXT
- Stock Information
- Founded
- YXT 2011
- RNXT 2012
- Country
- YXT China
- RNXT United States
- Employees
- YXT N/A
- RNXT N/A
- Industry
- YXT
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- YXT
- RNXT Health Care
- Exchange
- YXT NYSE
- RNXT Nasdaq
- Market Cap
- YXT 42.1M
- RNXT 44.6M
- IPO Year
- YXT 2024
- RNXT 2021
- Fundamental
- Price
- YXT $0.92
- RNXT $1.27
- Analyst Decision
- YXT
- RNXT Strong Buy
- Analyst Count
- YXT 0
- RNXT 2
- Target Price
- YXT N/A
- RNXT $7.25
- AVG Volume (30 Days)
- YXT 11.8K
- RNXT 157.7K
- Earning Date
- YXT 08-21-2025
- RNXT 08-12-2025
- Dividend Yield
- YXT N/A
- RNXT N/A
- EPS Growth
- YXT N/A
- RNXT N/A
- EPS
- YXT N/A
- RNXT N/A
- Revenue
- YXT $45,374,087.00
- RNXT $240,000.00
- Revenue This Year
- YXT N/A
- RNXT $3,186.05
- Revenue Next Year
- YXT N/A
- RNXT $291.93
- P/E Ratio
- YXT $1.50
- RNXT N/A
- Revenue Growth
- YXT N/A
- RNXT N/A
- 52 Week Low
- YXT $0.47
- RNXT $0.75
- 52 Week High
- YXT $11.00
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- RNXT 45.57
- Support Level
- YXT N/A
- RNXT $1.27
- Resistance Level
- YXT N/A
- RNXT $1.42
- Average True Range (ATR)
- YXT 0.00
- RNXT 0.06
- MACD
- YXT 0.00
- RNXT -0.02
- Stochastic Oscillator
- YXT 0.00
- RNXT 6.25
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.